Plasma Lipidomic Profiling and Risk of Type 2 Diabetes in the PREDIMED Trial
- PMID: 30327364
- PMCID: PMC6245212
- DOI: 10.2337/dc18-0840
Plasma Lipidomic Profiling and Risk of Type 2 Diabetes in the PREDIMED Trial
Abstract
Objective: Specific lipid molecular changes leading to type 2 diabetes (T2D) are largely unknown. We assessed lipidome factors associated with future occurrence of T2D in a population at high cardiovascular risk.
Research design and methods: We conducted a case-cohort study nested within the PREDIMED trial, with 250 incident T2D cases diagnosed during 3.8 years of median follow-up, and a random sample of 692 participants (639 noncases and 53 overlapping cases) without T2D at baseline. We repeatedly measured 207 plasma known lipid metabolites at baseline and after 1 year of follow-up. We built combined factors of lipid species using principal component analysis and assessed the association between these lipid factors (or their 1-year changes) and T2D incidence.
Results: Baseline lysophosphatidylcholines and lysophosphatidylethanolamines (lysophospholipids [LPs]), phosphatidylcholine-plasmalogens (PC-PLs), sphingomyelins (SMs), and cholesterol esters (CEs) were inversely associated with risk of T2D (multivariable-adjusted P for linear trend ≤0.001 for all). Baseline triacylglycerols (TAGs), diacylglycerols (DAGs), and phosphatidylethanolamines (PEs) were positively associated with T2D risk (multivariable-adjusted P for linear trend <0.001 for all). One-year changes in these lipids showed associations in similar directions but were not significant after adjustment for baseline levels. TAGs with odd-chain fatty acids showed inverse associations with T2D after adjusting for total TAGs.
Conclusions: Two plasma lipid profiles made up of different lipid classes were found to be associated with T2D in participants at high cardiovascular risk. A profile including LPs, PC-PLs, SMs, and CEs was associated with lower T2D risk. Another profile composed of TAGs, DAGs, and PEs was associated with higher T2D risk.
© 2018 by the American Diabetes Association.
Figures
References
-
- American Diabetes Association 2. Classification and diagnosis of diabetes. Diabetes Care 2017;40(Suppl. 1):S11–S24 - PubMed
-
- American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2008;31(Suppl. 1):S55–S60 - PubMed
-
- Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. . IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract 2017;128:40–50 - PubMed
-
- Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab 2009;5:150–159 - PubMed
-
- Chehade JM, Gladysz M, Mooradian AD. Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management. Drugs 2013;73:327–339 - PubMed
